Erectile dysfunction (ED) can have a strong negative effect on the well-being and quality of life of the sufferer. Many factors may contribute to the development of this disorder; age in particular and also concomitant chronic illnesses including neurological, hormonal, arterial and cavernosal factors. An understanding of the prevalence and characteristics of risk factors for ED is required, in order to establish effective therapeutic strategies. However, the prevalence of ED depends on the definitions used and the use of an internationally established scale for the assessment of male sexual function is necessary to facilitate the comparison of data between different countries.
Introduction
Although erectile dysfunction (ED) is not a lifethreatening disorder, it can have a strong negative effect on the daily routines, social interactions, well-being and quality of life of the sufferer. It is still difficult to estimate accurately the prevalence of ED worldwide. Little is known about variations in prevalence across geographic groups as ED is closely associated with racial, cultural, religious and socioeconomic factors. Moreover, it is difficult to establish the precise prevalence of ED due to limitations associated with the populations studied, the hesitancy of participants to answer questions and the unreliability of responses due to personal embarrassment.
Many etiologic factors may contribute to the development of ED. Impairment of psychological factors or the influence of age and concomitant chronic illnesses including neurological, hormonal, arterial and cavernosal factors are well-defined causes of ED. An understanding of the prevalence and characteristics of risk factors for ED is required in order to establish effective therapeutic strategies for this disorder. We review current knowledge about the prevalence and possible risk factors for ED and provide some insights into its prevention.
Aging
Selected studies of the prevalence of ED in different countries are shown in Table 1 . Most published surveys have concluded that ED is associated with aging.
The first study that demonstrated reliable data on the prevalence of ED in a large population sample was conducted by Kinsey et al. in 1948 . 1 This study evaluated 15 781 men in the general population of the United States of America who were classified by age, education, occupation and residence. Erectile dysfunction was found to be an age-dependent disorder with a prevalence ranging from 0.1% at 20 years of age to 75% at 80 years of age (Table 1) . Recently, the Massachusetts Male Aging Study (MMAS) provided information on the prevalence of ED in a general population of 1290 men aged 40-70 years, using specific validated questionnaires to measure its prevalence. 2 The data from the MMAS study suggested that the combined prevalence of minimal, moderate and complete ED was as high as 52%. The prevalence of minimal ED was 17%, while that of moderate and complete ED was 25% and 10%, respectively. 2 The prevalence of ED increased with age from 38% in the youngest group of men to almost 70% in the oldest men examined.
Data on the prevalence of ED in 3940 Japanese married men, aged 20-94 years, who underwent health examinations or were members of senior social clubs, were reported in 1995. 3 According to the survey associated with this study, approximately 2.5% of this population had complete or partial ED between the ages of 20 and 44 years, 10% between the ages of 45 and 59 years, 20% between the ages of 60 and 69 years and 33% between the ages of 70 and 79 years. The prevalence of ED increased markedly in men over 60 years of age.
The effects of aging on male sexual function were investigated in 967 male employees (aged 22-59 years) of 10 Japanese companies, using the International Index of Erectile Function (IIEF) questionnaire. 4 In subjects who were free from risk factors for sexual function (i.e. hypertension, diabetes mellitus, hyperlipidemia, heart diseases, strokes, malignant diseases of lower intestine or genitourinary tract and others), there was significant correlation between age and the scores for erectile function (EF), orgasmic function (OF), sexual desire (SD) and intercourse satisfaction (IS) (Fig. 1) . In China, the prevalence of ED was investigated in 1582 males aged over 40 years living in urban areas of Shanghai, who were randomly selected from family planning records. 5 The existence of ED was based on answers to questionnaires concerning lack of penile rigidity sufficient to penetrate the vagina or to maintain intercourse. The incidence of ED in older men was 32.8% at 40-49 years, 36.4% at 50-59 years, 74.2% at 60-69 years and 86.3% in those over 70 years.
In Nigeria, the incidence of erectile failure in 227 adult male medical outpatients at the University of Nigeria Teaching Hospital, was reported in 1990. 6 Thirty-four percent of the patients were affected by ED, and there was a significant correlation between ED and age, with the prevalence increasing progressively from 17% at 30-39 years to 75% in those aged 70 years or older.
Since Kinsey's original study, there have been numerous other epidemiological surveys conducted in selected populations with different medical problems, in the elderly, or in small patient samples.
7-10 Although they have been undertaken in different settings and with populations of different ages, all studies have shown that ED is associated with aging.
There is a clear age-related decrease in serum androgen levels, 11, 12 but it has not been convincingly demonstrated that a decreased serum-free testosterone concentration contributes to ED in aged men. A study in healthy aged men showed that free and albuminbound testosterone, but not total testosterone concentrations, were correlated positively with sexual desire and sleep-related erection, but not with erectile dysfunction or frequency of intercourse. 13 As changes in the structure of the tunica albuginea of the penis have also been implicated as a possible cause of ED in healthy elderly men, another study investigated whether such changes influence the development of ED.
14 It was concluded that decreased elastic fiber concentration and changes in microscopic features of the tunica albuginea may contribute to ED by impairing the veno-occlusive function of the penis.
Therefore, in general, there is no doubt that ED is associated with age, but it must be remembered that a wide range of medical problems and their treatment, which could potentially impair erectile function, are inevitably present or are increasingly being used in patients of advanced age.
Chronic diseases
A variety of diseases, surgery or trauma are directly associated with ED as they can cause vascular insufficiency, interruption of the nervous system, derangement of hormonal systems, changes in the microscopic structure of the tunica albuginea of the penis and the corpora cavernosa, or by impairment of psychological factors affecting the mood and behavior of patients (Table 2) .
Cardiovascular diseases
Cardiovascular diseases are a well-documented cause of arteriogenic ED, mainly via interference with the arterial inflow to the cavernous body. Erectile dysfunction may be associated with atherosclerotic vascular disease, peripheral vascular disease, hypertension or myocardial infarction (MI). In a previous study that investigated men leading ordinary lives, using the IIEF questionnaire, sexual functions were significantly impaired in men with hypertension or heart diseases ( Fig. 2 ). In a further study, the prevalence of ED in elderly men aged 60 years or over was significantly correlated with history of heart attack (i.e. ED occurred in 59% of those who had had a prior heart attack as compared with 35% of those who had not). 10 In the MMAS study, the ageadjusted probability for complete ED was 39% in men with treated heart disease, as compared to 15% in untreated hypertensive patients and 9.6% in the total sample. 2 An increased incidence of ED in hypertensive men has also been reported by others, 6, [15] [16] [17] suggesting that dysfunction may be worsened by the adverse effects of medications used to treat the condition.
Diabetes mellitus
Diabetes mellitus is one of the main systemic diseases causing ED. The mechanism by which diabetes causes ED is considered to involve multiple systems such as the autonomic nervous system, peripheral blood vessels and (sometimes) psychological factors. In a previous study, mean ± standard deviation IIEF scores for EF, OF, SD, IS and overall satisfaction (OS) for diabetic men aged in their 50s were 9.6 ± 8.1, 3.8 ± 4.0, 4.7 ± 2.0, 2.3 ± 3.9 and 5.6 ± 1.6, respectively. In contrast, these scores for non-diabetic men aged in their 50s were all higher at 21.3 ± 9.5, 7.4 ± 3.5, 6.4 ± 2.2, 7.4 ± 4.4 and 6.8 ± 2.3, respectively. 4 The prevalence of ED was found to be 7-fold greater in a group of 125 patients with non-insulindependent diabetes aged between 55 and 74 years than in 21 similarly aged controls. 18 In a study of 292 diabetic men and 81 non-diabetic men (all aged 20-59 years), the prevalence of ED in the two groups was 23% and 9%, respectively. 19 This report suggested that in diabetic men, ED is associated with hyperglycemia, stress and definite autonomic neuropathy. In the MMAS population, the age-adjusted probability of complete ED was 3-times greater in patients with treated diabetes than among controls without diabetes. 2 The prevalence of ED in the diabetic men varied from 27.5% to 59%, depending on age.
Chronic renal failure
Impaired EF is common in men with chronic renal failure, and the prevalence of ED has been reported to be as high as 45% in this setting. 20 The pathophysiology of ED in patients with renal failure is not clear, but hypogonadism due to dysfunctioning Leydig cells, hyperprolactinemia, hyperparathyroidism, anemia, protein malnutrition, zinc deficiency, hypertension and use of antihypertensive drugs have all been implicated.
Erectile dysfunction was noted in 50% of men aged between 23 and 53 years with chronic renal failure who had been on hemodialysis for more than one year. 21 In another study of 53 men with chronic renal failure, the prevalence of ED was 41.5% before hemodialysis, 64.2% after initiation of hemodialysis and 71.7% after kidney transplantation. 22 However, it has also been reported that almost all renal transplant recipients with grafts that function for more than three years regain their pre-illness level of sexual function. 23 
Fig. 2
International Index of Erectile Function scores for men in their 50s with or without cardiovascular disorders. EF, erectile function; OF, orgasmic function; SD, sexual desire; IS, intercourse satisfaction; OS, overall satisfaction. *P < 0.05 compared with normotensive men, †P < 0.01 compared with normotensive men. ᮀ Normotensive men; hypertensive men; men with heart disease. (Modified from Marumo K, Nagatsuma K, Murai M. Effect of aging and diseases on male sexual function assessed by the International Index of Erectile Function.
Jpn. J. Urol. 1999; 90: 911-19).

Liver failure
Liver failure is frequently associated with hypogonadism and gynecomastia, but the severity of ED is thought to depend on the severity of the liver failure. The mechanism involves conversion of androstenedione and testosterone to circulating estrogens. Severe ED occurs in patients with liver failure associated with a more than 50% reduction in plasma testosterone concentrations. 24 In men with alcoholic liver cirrhosis, the incidence of ED was found to be 70%, compared with 25% in men with non-alcoholic liver cirrhosis, 25 suggesting that the extent of ED depends on the cause of the liver failure.
Drug therapy
The role of some classes of drugs such as estrogens used in the treatment of prostatic cancer, antihypertensives and cardiac-active drugs in ED is well documented. With other pharmacological agents, for example, phenothiazines, antidiabetic agents and tricyclic antidepressants, a causative role is still controversial because of the frequent coexistence of other pathologic conditions or concomitant exposure to other drugs, although these agents are widely cited as contributing to ED in clinical evaluations. Patients often report improved sexual function following dosage reduction or discontinuance of these drugs. [26] [27] [28] [29] [30] [31] Drugs that may cause ED are listed in Table 3 .
Antihypertensive drugs
Almost all antihypertensive drugs tend to cause ED as an adverse effect. Propranolol and other b-adrenoceptor blockers have been implicated in the development of ED, especially at higher doses. [32] [33] [34] Thiazide diuretics reportedly cause decreased libido and ED in some patients, and this effect appears to be dose-related. 35 With reserpine, a centrally acting antihypertensive, sexual dysfunction reportedly includes decreased libido, gynecomastia and ED. 36 The mechanism of this adverse effect includes multiple factors such as central depression and an increase in serum prolactin concentrations. Methyldopa is also a centrally acting agent with a reported ED rate ranging up to 30% in those taking it. 17, 37 Suggested mechanisms for the adverse effect of this drug include sedation, depression and an increased serum prolactin concentration.
Other antihypertensives that have also been reported to cause ED include clonidine, a central a 2 -adrenoceptor agonist, 35 hydralazine, 35 guanethidine 36 and calcium channel blockers. 17 With clonidine, ED has been reported to be dose-related. 
Cardiac-active drugs
Long-term use of the cardiac glycoside digoxin has been reported to result in ED. Gynecomastia and decreased libido have also been reported with use of this drug. 38 The mechanism is unclear, but increased serum estrogen levels, and decreased luteinizing hormone (LH) and testosterone levels have been implicated. Disopyramide is an anti-arrhythmic drug with anticholinergic properties that may also cause ED.
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Hormones
Estrogens, progestins and luteinizing hormonereleasing hormone (LHRH) agonists used in the treatment of prostatic cancer frequently cause ED. Exogenous estrogens inhibit gonadotropin-releasing hormone and both estrogens and progestins increase serum prolactin concentrations. 27 Anabolic steroids may suppress endogenous steroid production, thereby possibly leading to ED on withdrawal. Administration of LHRH agonists has been reported to produce decreased libido in 92% of patients and ED in 86% of patients.
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Psychotherapeutic drugs
Erectile dysfunction has been reported in at least some patients treated with most drugs that produce central nervous system sedation or depression. This has been attributed to an elevation of serum prolactin concentrations, sedative effects, an anticholinergic effect, decreased dopaminergic activity or central effects on the limbic system.
28
Irradiation
Radiation-induced ED mostly occurs during the treatment of patients with prostatic cancer. Animal studies have suggested various mechanisms for this effect, including defects in the vascular supply of erectile tissue and of the nerves and smooth muscle. 41 Among patients who were potent prior to radiation therapy, 22% were found to be capable of a full erection and 41% were able to have a partial erection after radiation therapy. 42 In a study of the prevalence of ED in patients who had undergone external-beam radiation and radical prostatectomy, patients receiving radiation therapy had a lower rate of ED (23% vs 56% for men less than 70 years of age). 43 Erectile dysfunction can affect patients undergoing radiation therapy for prostatic cancer, but the severity of the ED depends on the radiation dose, the extent of radiation fields and the age of the patient.
Lifestyle factors
Smoking
Several epidemiological studies have suggested a correlation between ED and smoking and others have indicated that smoking might increase the likelihood of ED. Among a group of 178 patients with ED, the number of current smokers (58.4%) and current exsmokers combined (81%) was significantly higher than would be expected among males in the general population. 44 In each age group and at all levels of tobacco use, patients with ED smoked more than would be expected from population estimates. In a study of the correlation of ED with smoking in 4462 middle-aged men aged 31-49 years, the prevalence of ED was 2.2% among patients who had never smoked, 2.0% among former smokers and 3.7% among current smokers (P = 0.005). 45 Similarly, the MMAS study also demonstrated the correlation of smoking with the probability of ED development. 2 The association of ED with certain risk factors, such as heart disease and hypertension, was amplified in current cigarette smokers. In subjects with treated heart disease, the age-adjusted probability of complete ED was 56% for current smokers compared with 21% for current non-smokers. 
Alcohol consumption
Several studies have presented epidemiological data on the association between alcohol consumption and ED. In a study of the sexual attitudes and behavior of 50 hospitalized male alcoholics who were compared with a sample of the general population matched for age and social class, the incidence of ED was 54% in alcoholics as compared with 28% in the controls (P < 0.05). 46 Similarly, in a study that evaluated sexual dysfunction in male and female alcoholics and an agematched control group from a general practitioner's clinic, 63% of the male alcoholics reported sexual dysfunction, mainly erectile and libido disorders, as compared with 10% of the control group. 47 The patients claimed their problem began as soon as they started treatment with disulfiram (Antabuse).
Among cirrhotic patients who were liver transplant candidates, 14 out of 20 alcoholics had a history of ED as compared to 10 out of 40 who were not alcoholdependent, suggesting the significance of chronic alcohol consumption in the development of ED. 48 
Serum cholesterol levels
The role of high serum cholesterol concentrations as a risk factor for sexual disorders in men is controversial. In one study, men with a high-density lipoprotein (HDL) cholesterol concentration over 60 mg/ dL (1.55 mmol/L) had a 0.3-times higher risk of ED than men with a concentration below 30 mg/dL (0.78 mmol/L), while those with a total cholesterol (TC) concentration of more than 240 mg/dL (6.2 mmol/L) had a 1.83-times higher risk than those with a TC concentration less than 180 mg/dL (4.65 mmol/L). 48 In the MMAS study, HDL-cholesterol and serum dehydroepitestosterone levels were found to be inversely correlated with the probability of ED. 
Conclusions
Although this review has summarized the important literature concerning the epidemiology of ED and the major risk factors for ED development, the true incidence of ED in different countries and its prevalence due to individual risk factors are still difficult to ascertain. Because the prevalence of ED depends on the definitions used, the use of internationally established scales for the assessment of male sexual function may facilitate comparisons of data between different countries. There is also a need for well-controlled studies that are large enough to document even a small incidence of disease-or drug-related ED.
Further epidemiologic research and analysis of individual risk factors is required. Such studies will clarify the interactive effects of organic factors and their probable etiology with the general physical, sociocultural and psychologic status of patients. These efforts will lead to a reduction in unnecessary ED where substitution of treatment modalities for specific diseases is possible. Only then will it be possible to design more effective future strategies for the treatment and prevention of ED.
